Proactive Investors - Run By Investors For Investors
Why invest in SATI?
Sativa Group PLC: DEEP DIVE

Sativa Investments capitalises on first-mover advantage in UK medicinal cannabis

Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"
OVERVIEW: SATI The Big Picture
Sativa is the UK’s first medicinal cannabis investment vehicle
  • The UK’s first medicinal cannabis investment vehicle now an operating company with two fully trading UK businesses

  • Two commercial offtake agreements clinched with suppliers of cannabis oil in Portugal and Switzerland

  • Sativa to roll out CBD wellness retail centres and clinics


What Sativa Investments does:

Sativa Investments PLC (NEX:SATI) is Britain's first medicinal cannabis investment vehicle and is now an operating company with two fully trading UK businesses.

Listed on the NEX exchange in March 2018, Sativa was set up to make investments into Canada-based cannabis companies where the drug is now approved for medicinal and recreational use. 

Since the legalisation of medicinal cannabis in the UK in late 2018, Sativa has capitalised on its first-mover advantage to become a seed-to-consumer medicinal cannabis and cannabidiol (CBD) wellness business. 

It is now focused on the sourcing of raw material, advanced extraction, manufacture, testing, distribution, and research & development of cannabis products.

What Sativa Investments owns:

Sativa’s investments include: Canada-based pharmaceutical firm, Veritas Pharma Inc.; Canada pharma-tech business, Rapid Dose Therapeutics Inc., which owns the QuickStrip oral dissolving cannabis strips; and a 60% stake in a joint venture with Germany's Lexamed GmbH.

Its two operating subsidaries are testing facility, PhytoVista Laboratories, and George Botanicals, which develops, manufactures and distributes low-Tetrahydrocannabinol (THC) and CBD wellness products.

Inflexion points:

  • Sativa Investments announced in May that it plans to change its name to Sativa Group to reflect its reclassification as a trading company instead of an investment vehicle. Shareholders will vote on the proposal at the annual general meeting on June 12. 
  • Last month Sativa decided to abandon a plan to grow its own cannabis at a 7.5-acre Wiltshire site. The company believes sourcing raw material will provide greater returns than growing its own supply.
  • Sativa has signed commercial offtake agreements with two suppliers of cannabis oil for the manufacture of CBD products in the UK. These suppliers are Swiss firm, Alponics, and Portuguese cannabis oil supplier, MeridianTulip – Empresa Medicinal Lda.
  • Sativa turned a gross profit of £110,000 and a turnover of £260,000 in 2018 – its first year as a listed company. 
  • The group is planning to open its first of three Goodbody & Blunt wellness centre in Bath on June 28. The centre will sell a range of white label CBD products made by George Botanicals and other suppliers, all of which will be tested by Phytovista.
  • Sativa has teamed up with King's College London to research the impact of CBDs on inflammation and respiratory diseases. Under the research agreement, Sativa will supply the university with specific strains of cannabis plants that contain various combinations of the spectrum of at least 113 known CBDs, subject to regulatory approval.

What the CEO says: 

Geremy Thomas, founder and chief executive of Sativa, said in the group's 2018 results: "Sativa has delivered expeditiously on its investment promise to the market and is now recognised as a trading business, with two fully owned UK subsidiaries already performing well.

"This early stage traction within the marketplace proves the group's ability to deliver revenue-generating operations that benefit from first-mover advantage.

"The medicinal cannabis and CBD industries are highly complex and the twelve months of global research that I undertook before Saiva joined the NEX exchange is paying off. "

Join Proactive’s Crypto, Blockchain and Cannabis Telegram group here
View full SATI profile View Profile

Sativa Group PLC Timeline

Related Articles

April 30 2019
The health sciences company has five research and development programs, including gene therapy, its Sol-gel program for nose-to-brain delivery of medical compounds including cannabinoids, as well as non-addictive analgesic peptides as a replacement for morphine, fentanyl and oxycodone
April 30 2019
We take a look at a company with a unique approach to drug development that may ultimately help big pharma replenish its pipeline
June 07 2019
Geremy Thomas, founder and chief executive of Sativa, said the company has "delivered expeditiously on its investment promise to the market"

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use